KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Expenses (2023 - 2025)

Biocryst Pharmaceuticals' Operating Expenses history spans 9 years, with the latest figure at $146.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 7.44% year-over-year to $146.2 million; the TTM value through Dec 2025 reached $533.8 million, up 17.78%, while the annual FY2025 figure was $533.8 million, 17.78% up from the prior year.
  • Operating Expenses reached $146.2 million in Q4 2025 per BCRX's latest filing, up from $129.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $369.2 million in Q4 2023 to a low of $100.6 million in Q2 2024.
  • Average Operating Expenses over 3 years is $150.7 million, with a median of $129.8 million recorded in 2025.
  • Peak YoY movement for Operating Expenses: tumbled 63.15% in 2024, then surged 32.81% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $369.2 million in 2023, then crashed by 63.15% to $136.0 million in 2024, then grew by 7.44% to $146.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Operating Expenses are $146.2 million (Q4 2025), $129.8 million (Q3 2025), and $133.6 million (Q2 2025).